Kulasinghe Arutha, Kapeleris Joanna, Cooper Carolina, Warkiani Majid Ebrahimi, O'Byrne Kenneth, Punyadeera Chamindie
The School of Biomedical Sciences, Room 603D, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, QLD 4059, Australia.
Translational Research Institute, Brisbane, QLD 4102, Australia.
Cancers (Basel). 2019 Mar 18;11(3):380. doi: 10.3390/cancers11030380.
In non-small cell lung cancers (NSCLC), tumour biopsy can often be an invasive procedure. The development of a non-invasive methodology to study genetic changes via circulating tumour cells (CTCs) is an appealing concept. Whilst CTCs typically remain as rare cells, improvements in epitope-independent CTC isolation techniques has given rise to a greater capture of CTCs. In this cross sectional study, we demonstrate the capture and characterization of NSCLC CTCs for the clinically actionable markers epidermal growth factor receptor (EGFR) alterations, anaplastic lymphoma kinase (ALK) rearrangements and programmed death ligand-1 (PD-L1) expression. The study identified CTCs/CTC clusters in 26/35 Stage IV NSCLC patients, and subsequently characterized the CTCs for EGFR mutation, ALK status and PD-L1 status. This pilot study demonstrates the potential of a non-invasive fluid biopsy to determine clinically relevant biomarkers in NSCLC.
在非小细胞肺癌（NSCLC）中，肿瘤活检通常是一种侵入性操作。开发一种通过循环肿瘤细胞（CTC）研究基因变化的非侵入性方法是一个很有吸引力的概念。虽然CTC通常是罕见细胞，但与表位无关的CTC分离技术的改进使得对CTC的捕获量增加。在这项横断面研究中，我们展示了对NSCLC CTC的捕获和特征分析，以检测具有临床可操作性的标志物，即表皮生长因子受体（EGFR）改变、间变性淋巴瘤激酶（ALK）重排和程序性死亡配体-1（PD-L1）表达。该研究在35例IV期NSCLC患者中的26例中识别出CTC/CTC簇，随后对CTC进行了EGFR突变、ALK状态和PD-L1状态的特征分析。这项初步研究证明了非侵入性液体活检在确定NSCLC中临床相关生物标志物方面的潜力。
Zotero 插件
